CLINICAL PROFILE AND TREATMENT OUTCOMES OF CLASSICAL HODGKINS LYMPHOMA - SINGLE CENTRE EXPERIENCE
Authors: Arshad Mohamed Aaseem , Kannan J. , Joy Jiss 
Published: December 2024

Background: Classical Hodgkins lymphoma is one of the common hematological malignancies . With the advent of multiagent chemotherapy ,
radiotherapy in the frontline therapy and autologous stem cell transplantation in the relapsed setting , the overall survival of classical hodgkins
lymphoma patients have improved . We performed this study to analyse the clinical profile , treatment outcomes and survival data for patients
treated for cHL in our centre. A study sample from a database of patients treated at a tertiary car Methodology: e centre in South India between
January 2016 and december 2018 was analysed retrospectively. A total of 42 cHL patients were included in the study. Information regarding the
patient , tumor characteristics , details of upfront treatment , salvage chemotherapy and follow up details were collected retrospectively. The
collected data were analysed with IBM SPSS Statistics for Windows, Version 29.0.To describe about the data descriptive statistics , frequency
analysis, percentage analysis were used for categorical variables and the mean and S.D were used for continuous variables. To find the overall
Survival and progression free survival Kaplan-Meier curve with Log-rank method was used. The median Results: age is 21 years ( range : 13 - 69
years ) .Male to female ratio is 1.2:1 . The most common histology is nodular sclerosis (50%).28.6% of patients had early disease( stage 1 and 2) and
71.4% of patients had advanced disease .The most common presentation is lymphadenopathy (83%) , followed by fever(28.5%), loss of
weight(14.2%) and loss of apetite(7.1%) .73.8% of the patients received ABVD ,11.9% received ABVD/BEACOPP , 4.6% received EBVD ,
COPP/ABV and 2.3% received CEPP as frontline chemotherapy.21% of patients received radiation as a form of combined modality therapy and
11.9% of patients received radiation at the end of frontline chemotherapy for residual disease .The median follow up is 67 months .The 5 year
overall survival is 88.1% and 5 year progression free survival is 52.4% . The covariates that were found to be prognostic for survival is age(
P=0.003) and stage of the disease(P= 0.04) . The covariates that were prognostic for PFS were age of the patient (P=0.003) , stage of the disease
(P=0.002) and bone marrow involvement (P = 0.002) .47% (20) of patients relapsed following frontline chemotherapy. The most common salvage
chemotherapy used was ICE(70%) followed by GDP(60%) and DHAP(35%).The median salvage chemotherapy received in relapsed setting is 2 (
range 1 - 4 ) . 8 patients (40%) underwent ASCT as consolidation post salvage chemotherapy and 5 patients received RT to residual disease post
salvage therapy .One patient relapsed post autologous stem cell transplant .2 patients received only palliative chemotherapy in view of lack of
fitness to salvage therapy. The 5 year overall survival and 5 year PFS are only 85% and 52% respecti Conclusion: vely in our centre. Survival is very
low in elderly HL patients .So better frontline chemotherapy is required especially in the elderly population. Delayed presentation to oncologists
and lack of accessibility and affordability to standard of care drugs may be reasons for poorer survival in our population